I've been watching the biotech and information systems industries closely as strong Q2 earnings season leaders. These sectors have been carrying a bulk of recent stock rallies, bolstering major market indexes higher.
And today, I'm bringing you a Fast Profits options play tapped into two avenues of Big Tech profits.
This company doesn't just solve big problems for other large-cap tech leaders; it's a full-service cloud solutions platform, managing operations from the seed of an idea all the way to the realized benefit.
For those of us who aren't fintech whizzes, this is basically some of the highest-quality service you can get in this industry. I like to think of this company as a "supercharged" Quicken Inc. - typically the posterchild of cloud computing solutions among tech companies.
It recently released second-quarter earnings at $0.15 per share, exceeding expectations by a whopping 150%. This will be the fourth earnings beat in a row for this "next big thing" innovator... And with businesses across the globe preparing to hunker down into semi-permanent, virtual business models, given that the coronavirus is still running rampant, demand for today's Fast Profits stock to trade is only going to keep climbing.
See the full trade details in this, my latest edition of Fast Profits with Money Morning...
Could This Be the End of COVID-19?
Trade details:
Action to take No. 1: Buy shares of Model N Inc. (NYSE: MODN) using a limit order of $43.
Action to take No. 2: Buy to open MODN Feb. 19, 2021 $45 calls (MODN210219C00045000) using a limit order of $5.10.
One key takeaway from today's Fast Profits: The biotech sector will be minting loads of profitable opportunities in the coming months.
It's something we can clearly see in the above coverage of Model N, tackling the surging demand from the administrative side of the industry.
But there's one other clear path to profits emerging from the biotech sector now, a frontrunner in the race to create a vaccine for COVID-19.
In fact, the FDA just granted the "Super Vaccine" a fast track designation and backed the initiative with $483 million to help get the drug to market fast.
And this won't just mean a possible end to a grueling, six-month pandemic...
It could also ignite a 58,300% revenue surge.
Click here for the full details...
Follow Money Morning on Facebook and Twitter.[mmpazkzone name="end-story-hostage" network="9794" site="307044" id="138536" type="4"]
About the Author
Chris Johnson (“CJ”), a seasoned equity and options analyst with nearly 30 years of experience, is celebrated for his quantitative expertise in quantifying investors’ sentiment to navigate Wall Street with a deeply rooted technical and contrarian trading style.